Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients

Hypomethylating agents (HMA) like azacitidine are licensed for the treatment of acute myeloid leukemia (AML) patients ineligible for allogeneic hematopoietic stem cell transplantation. Biomarker-driven identification of HMA-responsive patients may facilitate the choice of treatment, especially in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Juliane, Simnica, Donjete, Jäkel, Nadja, Paschold, Lisa, Willscher, Edith, Schulze, Susann, Dierks, Christine, Al-Ali, Haifa Kathrin, Binder, Mascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799690/
https://www.ncbi.nlm.nih.gov/pubmed/35091554
http://dx.doi.org/10.1038/s41408-022-00615-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799690/
https://www.ncbi.nlm.nih.gov/pubmed/35091554
http://dx.doi.org/10.1038/s41408-022-00615-7

Ejemplares similares